TEVA
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Teva Pharmaceutical Industries Limited
- Nom
- Teva Pharmaceutical Industries Limited
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NYSE
- Capitalisation
- $45.9B
- Employés
- 32,008
- PDG
- Richard D. Francis
- Site web
- https://www.tevapharm.com
- Marché
- ALVOAMRXCIPLA.NSGLENMARK.NSRDYSDZNY
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 314 titres (~12153 USD)
- Insiders
- Savage Brian
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,141,974
Avg sell (VWAP, 90d window) $35.55 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,019,693 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-18
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-18 | Savage Brian | Sell · S | 314 | $38.70 | $12,153 | Form 4 |
| 2026-08-21 | Satchi-Fainaro Ronit | Sell · S | 415 | $37.25 | $15,459 | Form 4 |
| 2026-08-21 | Weiss Amir | Sell · S | 2,500 | $37.63 | $94,077 | Form 4 |
| 2026-08-17 | Lippman Evan | Sell · S · 10b5-1 | 18,600 | $36.57 | $680,291 | Form 4 |
| 2026-08-05 | Zaks Tal Zvi | Sell · S | 17 | $34.87 | $593 | Form 4 |
| 2026-08-03 | Hughes Eric A | Sell · S · 10b5-1 | 25,578 | $34.88 | $892,051 | Form 4 |
| 2026-08-03 | Jover Placid | Sell · S · 10b5-1 | 12,827 | $34.88 | $447,351 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-11-13 | Greg Gianforte | Purchase | $15,001 - $50,000 |
| 2020-05-07 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-06-19 | David Eugene Price | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
TEVA presents a compelling turnaround story in 2025, supported by improving profitability, a strengthening balance sheet, and strong pipeline catalysts including the FDA approval of DEGEVMA and a multi-biosimilar…
The first sentence of the analysis written for TEVA on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.04 · operating margin 12%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% | |
| Ebit Margin | 12.4% | 20.4% | 2.6% | -15.0% | 19.4% | |
| Ebitda Margin | 18.2% | 26.8% | 9.8% | -6.2% | 27.8% | |
| Operating Profit Margin | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% | |
| Pretax Profit Margin | 7.2% | -7.8% | -3.9% | -21.1% | 4.2% | |
| Continuous Operations Profit Margin | 8.2% | -11.8% | -3.9% | -16.7% | 2.9% | |
| Net Profit Margin | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | |
| Bottom Line Profit Margin | 8.2% | -9.9% | -3.5% | -16.4% | 2.6% | |
| Current Ratio | 1.036 | 0.981 | 1.019 | 1.051 | 1.140 | |
| Quick Ratio | 0.800 | 0.746 | 0.691 | 0.717 | 0.794 | |
| Solvency Ratio | 0.073 | -0.017 | 0.017 | -0.032 | 0.048 | |
| Cash Ratio | 0.264 | 0.258 | 0.263 | 0.244 | 0.196 | |
| Price To Earnings Ratio | 25.374 | -15.200 | -20.880 | -4.145 | 21.079 | |
| Price To Earnings Growth Ratio | -0.137 | -0.080 | 0.270 | 0.006 | -0.191 | |
| Forward Price To Earnings Growth Ratio | -0.137 | -0.080 | 0.270 | 0.006 | -0.191 | |
| Price To Earnings Diluted Ratio | 26.008 | -15.200 | -20.880 | -4.145 | 21.079 | |
| Price To Earnings Diluted Growth Ratio | -0.142 | -0.080 | 0.270 | 0.006 | -0.191 | |
| Price To Book Ratio | 4.534 | 4.639 | 1.556 | 1.297 | 0.859 | |
| Price To Sales Ratio | 2.078 | 1.507 | 0.737 | 0.678 | 0.556 | |
| Price To Free Cash Flow Ratio | 31.237 | 33.281 | 13.875 | 9.715 | 37.403 | |
| Price To Operating Cash Flow Ratio | 21.747 | 19.990 | 8.540 | 6.367 | 11.061 | |
| Debt To Assets Ratio | 0.427 | 0.460 | 0.464 | 0.490 | 0.492 | |
| Debt To Equity Ratio | 2.197 | 3.365 | 2.685 | 2.763 | 2.282 | |
| Debt To Capital Ratio | 0.687 | 0.771 | 0.729 | 0.734 | 0.695 | |
| Long Term Debt To Capital Ratio | 0.659 | 0.749 | 0.708 | 0.710 | 0.678 | |
| Financial Leverage Ratio | 5.151 | 7.319 | 5.793 | 5.640 | 4.638 | |
| Working Capital Turnover Ratio | 140.305 | -5,514.667 | 38.646 | 14.027 | 22.895 | |
| Operating Cash Flow Ratio | 0.123 | 0.097 | 0.112 | 0.139 | 0.072 | |
| Operating Cash Flow Sales Ratio | 0.096 | 0.075 | 0.086 | 0.107 | 0.050 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.696 | 0.601 | 0.615 | 0.655 | 0.296 | |
| Debt Service Coverage Ratio | 1.214 | 1.380 | 0.579 | -0.093 | 1.812 | |
| Interest Coverage Ratio | 2.355 | -0.322 | 0.421 | -2.362 | 1.926 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.906 | 0.700 | 0.818 | 0.754 | 0.560 | |
| Operating Cash Flow Coverage Ratio | 0.095 | 0.069 | 0.068 | 0.074 | 0.034 | |
| Capital Expenditure Coverage Ratio | 3.291 | 2.504 | 2.601 | 2.901 | 1.420 | |
| Dividend Paid And Capex Coverage Ratio | 3.291 | 2.504 | 2.601 | 2.901 | 1.420 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.819 | 8.961 | 18.363 | -31.225 | 6.832 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 51.8% | ▲3.1% | ▲3.1% |
| Ebit Margin | 12.4% | ▼-8.0% | ▲4.4% |
| Ebitda Margin | 18.2% | ▼-8.6% | ▲2.9% |
| Operating Profit Margin | 12.5% | ▲14.3% | ▲10.6% |
| Pretax Profit Margin | 7.2% | ▲14.9% | ▲11.5% |
| Continuous Operations Profit Margin | 8.2% | ▲20.1% | ▲12.5% |
| Net Profit Margin | 8.2% | ▲18.1% | ▲12.0% |
| Bottom Line Profit Margin | 8.2% | ▲18.1% | ▲12.0% |
| Current Ratio | 1.036 | ▲0.056 | ▼-0.009 |
| Quick Ratio | 0.800 | ▲0.054 | ▲0.051 |
| Solvency Ratio | 0.073 | ▲0.091 | ▲0.056 |
| Cash Ratio | 0.264 | ▲0.006 | ▲0.019 |
| Price To Earnings Ratio | 25.374 | ▲40.574 | ▲24.128 |
| Price To Earnings Growth Ratio | -0.137 | ▼-0.057 | ▼-0.111 |
| Forward Price To Earnings Growth Ratio | -0.137 | ▼-0.057 | ▼-0.111 |
| Price To Earnings Diluted Ratio | 26.008 | ▲41.208 | ▲24.636 |
| Price To Earnings Diluted Growth Ratio | -0.142 | ▼-0.062 | ▼-0.115 |
| Price To Book Ratio | 4.534 | ▼-0.106 | ▲1.956 |
| Price To Sales Ratio | 2.078 | ▲0.571 | ▲0.967 |
| Price To Free Cash Flow Ratio | 31.237 | ▼-2.043 | ▲6.135 |
| Price To Operating Cash Flow Ratio | 21.747 | ▲1.757 | ▲8.206 |
| Debt To Assets Ratio | 0.427 | ▼-0.033 | ▼-0.040 |
| Debt To Equity Ratio | 2.197 | ▼-1.167 | ▼-0.461 |
| Debt To Capital Ratio | 0.687 | ▼-0.084 | ▼-0.036 |
| Long Term Debt To Capital Ratio | 0.659 | ▼-0.090 | ▼-0.042 |
| Financial Leverage Ratio | 5.152 | ▼-2.168 | ▼-0.557 |
| Working Capital Turnover Ratio | 140.305 | ▲5654.971 | ▲1200.063 |
| Operating Cash Flow Ratio | 0.122 | ▲0.025 | ▲0.014 |
| Operating Cash Flow Sales Ratio | 0.096 | ▲0.020 | ▲0.013 |
| Free Cash Flow Operating Cash Flow Ratio | 0.696 | ▲0.096 | ▲0.123 |
| Debt Service Coverage Ratio | 1.214 | ▼-0.166 | ▲0.235 |
| Interest Coverage Ratio | 2.355 | ▲2.677 | ▲1.951 |
| Short Term Operating Cash Flow Coverage Ratio | 0.906 | ▲0.206 | ▲0.159 |
| Operating Cash Flow Coverage Ratio | 0.095 | ▲0.026 | ▲0.027 |
| Capital Expenditure Coverage Ratio | 3.291 | ▲0.787 | ▲0.748 |
| Dividend Paid And Capex Coverage Ratio | 3.291 | ▲0.787 | ▲0.748 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.819 | ▲6.857 | ▲12.069 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $35.86B | $24.93B | $11.68B | $10.12B | $8.83B | |
| Enterprise value | $49.69B | $39.71B | $28.61B | $28.88B | $30.12B | |
| EV / Sales | 2.88x | 2.40x | 1.81x | 1.94x | 1.90x | |
| EV / Op. cash flow | 30.13x | 31.84x | 20.91x | 18.17x | 37.75x | |
| EV / Free cash flow | 43.28x | 53.01x | 33.98x | 27.72x | 127.63x | |
| EV / EBITDA | 15.82x | 8.96x | 18.36x | -31.23x | 6.83x | |
| Net debt / EBITDA | 4.40x | 3.33x | 10.87x | -20.28x | 4.83x | |
| Current ratio | 1.04x | 0.98x | 1.02x | 1.05x | 1.14x | |
| Income quality | 1.16x | -0.64x | -2.22x | -0.64x | 1.75x | |
| Graham number | $14 | — | — | — | $9 | |
| Graham net-net | -$22 | -$23 | -$25 | -$25 | -$26 | |
| Tax burden | 113.9% | 127.7% | 89.9% | 77.8% | 62.5% | |
| Interest burden | 57.9% | -38.0% | -153.6% | 140.7% | 21.7% | |
| Working capital | $490.0M | -$244.0M | $238.0M | $582.0M | $1.55B | |
| Invested capital | $24.70B | $24.27B | $28.95B | $30.64B | $35.53B | |
| Return on assets | 3.5% | -4.2% | -1.3% | -5.6% | 0.9% | |
| Operating ROA | 5.4% | -0.7% | 1.0% | -4.8% | 3.5% | |
| Return on tangible assets | 6.7% | -8.3% | -2.7% | -12.2% | 2.1% | |
| Return on equity | 17.8% | -30.5% | -7.4% | -31.3% | 4.1% | |
| Return on invested capital | 7.4% | -1.1% | 1.3% | -5.0% | 3.1% | |
| Return on capital employed | 7.9% | -1.1% | 1.4% | -6.8% | 4.7% | |
| Earnings yield | 3.9% | -6.6% | -4.8% | -24.2% | 4.7% | |
| Free cash flow yield | 3.2% | 3.0% | 7.2% | 10.3% | 2.7% | |
| Capex / Op. cash flow | 30.4% | 39.9% | 38.5% | 34.5% | 70.4% | |
| Capex / Depreciation | 50.0% | 47.0% | 45.6% | 41.9% | 42.3% | |
| Capex / Sales | 2.9% | 3.0% | 3.3% | 3.7% | 3.5% | |
| SG&A / Sales | 23.0% | 22.4% | 22.1% | 23.1% | 22.2% | |
| R&D / Sales | 5.9% | 6.4% | 6.0% | 5.6% | 6.9% | |
| Stock comp / Sales | 0.9% | 0.7% | 0.8% | 0.8% | 0.7% | |
| Intangibles / Total assets | 48.5% | 49.8% | 51.9% | 54.3% | 57.7% | |
| Days sales outstanding | 78d | 67d | 79d | 90d | 104d | |
| Days payables outstanding | 111d | 95d | 116d | 87d | 74d | |
| Operating cycle | 218d | 197d | 257d | 266d | 272d | |
| Cash conversion cycle | 107d | 102d | 142d | 180d | 198d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-02 Journal of Child Neurology Publishes Review Highlighting Dopamine''s Role in Tourette Syndrome and Ecopipam''s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The review evaluates current treatment limitations and details how selectively targeting D1 receptors in the brain''s direct motor pathway may offer a differentiated, non-antipsychotic approach for managing tics in pediatric patients.1
- 2026-10-02 Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson''s Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data include a post hoc analysis of safety and efficacy during the initial 8 weeks of treatment with ecopipam, long-term efficacy and safety from an interim analysis of an ongoing open-label extension (OLE) study, post hoc subgroup analyses and preclinical receptor selectivity findings.
- 2026-10-01 Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More Wall Street analysts reshuffled their bets on energy giants, homebuilders, and emerging space plays on Thursday, and the moves cut in some surprising directions for names investors thought they had figured out.
- 2026-10-01 Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- #Fasenra--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab). Un.
- 2026-09-30 TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer.
- 2026-09-29 Teva''s Branded Drugs Take Center Stage in Its Growth Strategy Teva''s branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.
- 2026-09-29 Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround Forecasts call for Teva''s branded drug portfolio to bring it $3.7 billion in revenue next year. At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rating.
- 2026-09-28 Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva® (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.
- 2026-09-26 QRG Capital Management Inc. Purchases 12,925 Shares of Teva Pharmaceutical Industries Ltd. $TEVA QRG Capital Management Inc. grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 17.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,078 shares of the company''s stock after purchasing an additional 12,925 shares during the period. QRG Capital
- 2026-09-24 Teva Eyes New Growth Phase After Securing Investment-Grade Ratings Teva Pharmaceutical Industries (NYSE: TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference. Francis said the company achieved the milestone about a year earlier than its prior target of the end of 2027. He said